Ajanta Pharma Limited, has launched levetiracetam immediate-release tablets (250mg, 500mg, 750mg, 1000mg) in US market through its wholly owned subsidiary Ajanta Pharma USA Inc. Levetiracetam cures epileptic neurological disorder like numbness, blindness, paralysis or fits and is a bioequivalent generic version of Keppra.
Ajanta Pharma’s launch of levetiracetam tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. To date, the US FDA has granted Ajanta Pharma eight ANDA final approvals and two tentative approvals. Additional 16 ANDAs are under review with FDA.